Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.68 USD
Change Today -0.05 / -1.06%
Volume 155.0K
ECYT On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/10/14 - $6.89
52 Week Low
09/29/15 - $4.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENDOCYTE INC (ECYT)

endocyte inc (ECYT) Related Businessweek News

No Related Businessweek News Found

endocyte inc (ECYT) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat cancer; EC1669, which is in preclinical development stage to treat inflammatory diseases; and EC0371 that is in preclinical development stage for the treatment of polycystic kidney disease. In addition, it develops Etarfolatide, a companion imaging agent for its SMDCs that target folate receptor; and EC0652, a diagnostic imaging agent targeting prostate-specific membrane antigen. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of Vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

81 Employees
Last Reported Date: 03/13/15
Founded in 1995

endocyte inc (ECYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $475.6K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $208.7K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $323.0K
Vice President of Research & Development
Total Annual Compensation: $278.5K
Vice President of Clinical Operations
Total Annual Compensation: $261.8K
Compensation as of Fiscal Year 2014.

endocyte inc (ECYT) Key Developments

Endocyte to Present Data on EC1456 at the European Cancer Congress 2015

Endocyte, Inc. announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the European Cancer Congress 2015, being held Sept. 25 - 29, 2015, in Vienna, Austria. EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors.

Endocyte, Inc. Announces Final Overall Survival Results From Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Patients

Endocyte, Inc. presented the final overall survival analysis from the Phase 2b TARGET trial evaluating its small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC at the World Conference on Lung Cancer in Denver, Colorado. Vintafolide plus docetaxel improved overall survival by 2.7 months in NSCLC regardless of histology (Median OS 11.5 vs. 8.8 months, OS HR=0.86, 95% CI [0.58, 1.26]). In the predefined subset analysis of patients with adenocarcinoma, which expresses higher levels of folate receptor, vintafolide plus docetaxel improved OS by 5.9 months (12.5 vs. 6.6 months, HR=0.72, 95% CI [0.44, 1.16]). OS for vintafolide as single agent was similar to docetaxel (OS 8.4 vs. 8.8 months, HR=1.02, 95% CI [0.70, 1.50]). The study previously reported that the PFS primary endpoint was met, (HR=0.75, 95% CI [0.52, 1.09]) regardless of histology and in the adenocarcinoma subgroup (HR=0.73, 95% CI [0.46, 1.16]). The safety profile of the combination arm was consistent with those observed with docetaxel alone and vintafolide alone, though a higher rate of hematologic and peripheral neuropathy adverse events were observed in the combination arm. EC1456 is a second generation folate-targeted SMDC, which delivers a more potent drug payload at higher doses than vintafolide.

Endocyte, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM

Endocyte, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM. Venue: Sofitel Hotel, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $4.68 USD -0.05

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ECYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 50.3x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at